These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 28154831)

  • 21. Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients.
    Yu J; Wu X; Yan J; Yu H; Xu L; Chi Z; Sheng X; Si L; Cui C; Dai J; Ma M; Xu T; Kong Y; Guo J
    J Hematol Oncol; 2018 Jan; 11(1):1. PubMed ID: 29298689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells.
    Yvon E; Del Vecchio M; Savoldo B; Hoyos V; Dutour A; Anichini A; Dotti G; Brenner MK
    Clin Cancer Res; 2009 Sep; 15(18):5852-60. PubMed ID: 19737958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ganglioside GD2 in reception and transduction of cell death signal in tumor cells.
    Doronin II; Vishnyakova PA; Kholodenko IV; Ponomarev ED; Ryazantsev DY; Molotkovskaya IM; Kholodenko RV
    BMC Cancer; 2014 Apr; 14():295. PubMed ID: 24773917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An epitope common to gangliosides O-acetyl-GD3 and GD3 recognized by antibodies in melanoma patients after active specific immunotherapy.
    Ravindranath MH; Morton DL; Irie RF
    Cancer Res; 1989 Jul; 49(14):3891-7. PubMed ID: 2472199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chimeric antibodies with specificity for tumor antigens: demonstration of in situ localization to tumors after antibody therapy.
    Saleh MN; Tilden AB; Meredith RF; LoBuglio AF; Grizzle WE
    Biotech Histochem; 1998 Jul; 73(4):186-97. PubMed ID: 9735877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes.
    Riemer AB; Förster-Waldl E; Brämswig KH; Pollak A; Zielinski CC; Pehamberger H; Lode HN; Scheiner O; Jensen-Jarolim E
    Eur J Immunol; 2006 May; 36(5):1267-74. PubMed ID: 16568495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice.
    Wondimu A; Zhang T; Kieber-Emmons T; Gimotty P; Sproesser K; Somasundaram R; Ferrone S; Tsao CY; Herlyn D
    Cancer Immunol Immunother; 2008 Jul; 57(7):1079-89. PubMed ID: 18157673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disialoganglioside GD2 and a novel tumor antigen: potential targets for immunotherapy of desmoplastic small round cell tumor.
    Modak S; Gerald W; Cheung NK
    Med Pediatr Oncol; 2002 Dec; 39(6):547-51. PubMed ID: 12376975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-GD2 antibody therapy for GD2-expressing tumors.
    Navid F; Santana VM; Barfield RC
    Curr Cancer Drug Targets; 2010 Mar; 10(2):200-9. PubMed ID: 20201786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer vaccines: an update with special focus on ganglioside antigens.
    Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
    Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of tumor-cell lysis by bi-specific antibody recognizing ganglioside GD2 and T-cell antigen CD3.
    Bernhard H; Karbach J; Strittmatter W; Meyer zum Büschenfelde KH; Knuth A
    Int J Cancer; 1993 Sep; 55(3):465-70. PubMed ID: 8375931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of cellular immunity by anti-idiotypic antibodies mimicking GD2 ganglioside.
    Basak S; Birebent B; Purev E; Somasundaram R; Maruyama H; Zaloudik J; Swoboda R; Strittmatter W; Li W; Luckenbach A; Song H; Li J; Sproesser K; Guerry D; Nair S; Furukawa K; Herlyn D
    Cancer Immunol Immunother; 2003 Mar; 52(3):145-54. PubMed ID: 12649743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of 9-O-acetyl-N-acetylneuraminic acid (Neu5,9Ac
    Cavdarli S; Dewald JH; Yamakawa N; Guérardel Y; Terme M; Le Doussal JM; Delannoy P; Groux-Degroote S
    Glycoconj J; 2019 Feb; 36(1):79-90. PubMed ID: 30612272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
    Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
    Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2.
    Foon KA; Sen G; Hutchins L; Kashala OL; Baral R; Banerjee M; Chakraborty M; Garrison J; Reisfeld RA; Bhattacharya-Chatterjee M
    Clin Cancer Res; 1998 May; 4(5):1117-24. PubMed ID: 9607568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma.
    Marx S; Wilken F; Wagner I; Marx M; Troschke-Meurer S; Zumpe M; Bien-Moeller S; Weidemeier M; Baldauf J; Fleck SK; Rauch BH; Schroeder HWS; Lode H; Siebert N
    J Neurooncol; 2020 May; 147(3):577-585. PubMed ID: 32246395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides.
    Zhang S; Cordon-Cardo C; Zhang HS; Reuter VE; Adluri S; Hamilton WB; Lloyd KO; Livingston PO
    Int J Cancer; 1997 Sep; 73(1):42-9. PubMed ID: 9334808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disialoganglioside GD2 as a therapeutic target for human diseases.
    Suzuki M; Cheung NK
    Expert Opin Ther Targets; 2015 Mar; 19(3):349-62. PubMed ID: 25604432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disialoganglioside directed immunotherapy of neuroblastoma.
    Modak S; Cheung NK
    Cancer Invest; 2007 Feb; 25(1):67-77. PubMed ID: 17364560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.
    Perez Horta Z; Goldberg JL; Sondel PM
    Immunotherapy; 2016 Sep; 8(9):1097-117. PubMed ID: 27485082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.